

Table S1. Antibodies used in the study.

Antibody name&species	Company	Cargo number
Rabbit Anti-ATF3	Cell Signaling Technology	33593
Rabbit Anti-HDAC6	Cell Signaling Technology	7612S
Rabbit Anti-H3	Huabio Technology	ET1701-64
Rabbit Anti-H3K9ac	Cell Signaling Technology	9649T
Rabbit Anti-H3K14ac	Huabio Technology/ Active motif	ET1706/3959
Rabbit Anti-H3K18ac	Huabio Technology	HA500047
Rabbit Anti-H3K27ac	Cell Signaling Technology	8173S
Rabbit Anti- $\alpha$ -SMA	Abcam	ab5694
Rabbit Anti-Collagen I	Boster Biological Technology	PB0981
RabbitAnti-Fibronectin	Affinity Biosciences	AF5335
RabbitAnti-Collagen VI	Huabio Technology	ET1612-91
Mouse Anti-TGF- $\beta$ 1	Affinity Biosciences	BF8012
Rabbit Anti- phospho-Smad3	Huabio Technology	ET1607-43
Rabbit Anti-Smad3	Huabio Technology	ET1609-41
Rabbit Anti-Smad7	Huabio Technology	ER1912-61
Rabbit Anti-GAPDH	Affinity Biosciences	AF7021

Table S2. Primer sequences used in qPCR.

Gene	Sequences
<i>Hprt</i>	Forward 5'-TCAGTCAACGGGGGACATAAA-3' Reverse 5'-GGGGCTGTACTGCTTAACCAG-3'
<i>Atf3</i>	Forward 5'-TTTGCTAACCTGACACCCTTTG-3' Reverse 5'-AGAGGACATCCGATGGCAGA-3'
<i>Tgfb1</i>	Forward 5'-CCACCTGCAAGACCATCGAC -3' Reverse 5'-CTGGCGAGCCTTAGTTTGGAC -3'
<i><math>\alpha</math>-sma</i>	Forward 5'-CCCAGACATCAGGGAGTAATGG -3' Reverse 5'-TCTATCGGATACTTCAGCGTCA-3'
<i>Collagen I</i>	Forward 5'-GCTCCTCTTAGGGGCCACT-3' Reverse 5'-ATTGGGGACCCTTAGGCCAT-3'
<i>Collagen IV</i>	Forward 5'-CCTGGCACAAAAGGGACGA-3' Reverse 5'-ACGTGGCCGAGAATTCACC-3'
<i>Fibronectin</i>	Forward 5'-ATGTGGACCCCTCCTGATAGT-3' Reverse 5'-GCCCAGTGATTTCAGCAAAGG-3'
<i>Smad2</i>	Forward 5'-AAGCCATCACCCTCAGAATTG-3' Reverse 5'-CACTGATCTACCGTATTTGCTGT-3'
<i>Smad3</i>	Forward 5'-AGGGGCTCCCTCACGTTATC-3' Reverse 5'-CATGGCCCGTAATTCATGGTG-3'
<i>Smad4</i>	Forward 5'-ACACCAACAAGTAACGATGCC-3' Reverse 5'-GCAAAGGTTTCACTTTCCCCA-3'
<i>Smad7</i>	Forward 5'-TTTTCTCAAACCAACTGCAGGC-3' Reverse 5'-AATTGAGCTGTCCGAGGCAA-3'
<i>Hdac1</i>	Forward 5'-TGAAGCCTCACCGAATCCG-3' Reverse 5'-GGGCGAATAGAACGCAGGA-3'
<i>Hdac2</i>	Forward 5'-GGAGGAGGCTACACAATCCG-3' Reverse 5'-TCTGGAGTGTTCTGGTTTGTCA-3'
<i>Hdac3</i>	Forward 5'-GCCAAGACCGTGGCGTATT-3' Reverse 5'-GTCCAGCTCCATAGTGGAAGT-3'

<i>Hdac4</i>	Forward 5'-CTGCAAGTGGCCCCTACAG-3'
	Reverse 5'-CTGCTCATGTTGACGCTGGA-3'
<i>Hdac5</i>	Forward 5'-AGCACCGAGGTAAAGCTGAG-3'
	Reverse 5'-GAACTCTGGTCCAAAGAAGCG-3'
<i>Hdac6</i>	Forward 5'-TCCACCGGCCAAGATTCTTC-3'
	Reverse 5'-GCCTTTCTTCTTTACCTCCGCT-3'
<i>Hdac7</i>	Forward 5'-TTCCTGGCAGGCTTACACC-3'
	Reverse 5'-ATGGACTGTTCTCTCAAGGGC-3'
<i>Hdac8</i>	Forward 5'-ACTATTGCCGGAGATCCAATGT-3'
	Reverse 5'-CCTCCTAAAATCAGAGTTGCCAG-3'
<i>Hdac9</i>	Forward 5'-GCGGTCCAGGTAAAACAGAA-3'
	Reverse 5'-GCCACCTCAAACACTCGCTT-3'
<i>Hdac10</i>	Forward 5'-ACAGCCACTCGACTGCTCT-3'
	Reverse 5'-GATGCCTCACAAGCTGACAAA-3'
<i>Hdac11</i>	Forward 5'-GTGTACTCACCACGTTACAACA-3'
	Reverse 5'-GCTCGTTGAGATAGCGCCTC-3'

---


Table S3. Clinical data of patients with different causes of CKD.

Patient	Age at biopsy (yr)	Gender	Diagnoses	Scr ( $\mu\text{mol/L}$ )	eGFR (mL/min/1.73m <sup>2</sup> )
1	48	M	RCC	78	97.86
2	44	M	MN	95	83.53
3	30	F	IgAN	91	73.17
4	28	F	FSGS	153	39.54
5	50	F	AAV	344	12.74
6	48	F	DN	82	73.65

Scr, serum creatinine; eGFR, estimated glomerular filtration rate; F, female; M, male; RCC, renal cell carcinoma; MN, membranous nephropathy; IgAN, IgA nephropathy; FSGS, focal segmental glomerulosclerosis; AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; DN, diabetic nephropathy.


Table S4. Primer sequences used in ChIP-qPCR.

Gene	Sequences
<i>SMAD7</i>	Forward5'-CCGCCAGCTTGGGTATATGT-3'
	Reverse5'-GTTTCTGGGCCTCGTAGCTT-3'




**Figure S1. ATF3 was the major responding ATF in renal interstitial fibrosis and was**

**induced in tubular epithelial cells.** (A) UMAP for single cell data in IRI/UUO mouse kidneys. (B) Kidney tissue atlas from Kidney Precision Medicine Project showing ATF3 enrichment in CKD patients' kidneys. (C) Immunohistochemistry staining ( $\times 200$ , scale bar = 50  $\mu\text{m}$ ) of ATF3 in UUO, adenine, FA and cisplatin-CKD mouse kidneys and relative controls. (D) Immunofluorescence ( $\times 400$ , scale bar = 50  $\mu\text{m}$ ) of ATF3 double-stained with in UUO and control kidneys.






**Figure S2. Atf3 knockout protected against UUO/adenine-induced renal interstitial fibrosis and suppressed TGF- $\beta$ /Smad3 signaling.** (A) Immunoblot scoring of ATF3 in UUO kidneys. (B) Serum creatinine and urea in adenine nephropathy. (C) Immunoblot and scoring of ATF3 in adenine kidneys. (D) Immunoblot scorings of fibrotic markers and TGF- $\beta$ /Smad3 signaling in UUO kidneys. (E) Photomicrographs illustrated HE ( $\times 200$ , scale bar = 50  $\mu\text{m}$  /400, scale bar = 20  $\mu\text{m}$ ) staining and tubular injury scores in adenine kidneys. (F) MASSON ( $\times 200$ , scale bar = 50  $\mu\text{m}$  /400, scale bar = 20  $\mu\text{m}$ ) staining with positive area measurements in adenine kidneys. (G) Immunoblots and scorings of fibrotic markers and TGF- $\beta$ /Smad3 signaling in adenine kidneys.




**Figure S3. Volcano plots, KEGG analysis, and ATF3 binding data.** (A) Volcano plots between WT sham vs. UUO kidneys. (B) Volcano plots between WT UUO vs. Atf3 KO UUO kidneys. (C) KEGG analysis between WT sham vs. UUO kidneys. (D) KEGG analysis between WT UUO vs. Atf3 KO UUO kidneys. (E) The UCSC genome browser database showed ATF3 was found to bind to *Smad7* gene in multiple cell lines of human origin. (F) Luciferase reporter gene assay procedure of ATF3 on *SMAD7* transcriptional activity.

**Tcmk-1 cell line**


→  **Pcmv-ATF3 transfection**

→ 24 h → +/- TGF- $\beta$ 1 (20 ng/mL) → 24 h → Cell collection

→  **Pcmv-ATF3+HDAC6 siRNA transfection**

**Figure S4. IHC staining of HDAC6 in kidneys and TCMK-1 cell grouping.** (A) Immunocytochemistry staining ( $\times 200$ , scale bar = 50  $\mu\text{m}$ ) of HDAC6 in kidneys. (B) The procedures and grouping of TCMK-1 cells with TGF- $\beta$ 1 stimulation. (C) The procedures and grouping of TCMK-1 cells without TGF- $\beta$ 1 stimulation.

A



B







Figure S5. The siRNAs from mouse and human origin both successfully decreased


**HDAC6 transcription and expression in TCMK-1 and 293T cell line, respectively.** (A) Quantitative real-time PCR analysis and immunoblot of HDAC6 in TCMK-1 cells. (B) Quantitative real-time PCR analysis and immunoblot of HDAC6 in 293T cells. \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .






**Figure S6. Immunoblot scorings of multiple acetylation locations in H3 in UUO kidneys, primary TECs or TCMK-1 cells.** (A) Immunoblot scorings of H3K9ac, H3K14ac, H3K18ac, H3K27ac in UUO kidneys. (B) Immunoblot scorings of HDAC6, H3K14ac in primary TECs. (C) Immunoblot scorings of HDAC6, H3K14ac in TCMK-1 cells. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\*\* $p < 0.0001$ .


A



B




C




**Figure S7. Quantitative real-time PCR analysis of *HDAC6* and immunoblots of HDAC6/H3K14ac in 293T cells. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .**


A



B




C




**Figure S8. Immunoblot scorings in primary TECs / TCMK-1 cells and the TGF- $\beta$ 1 concentrations in supernatants of each 293T cell group.** (A) Immunoblot scoring of ATF3 and fibrotic markers in primary TECs. (B) Immunoblot scoring of TGF- $\beta$ /Smad3 signaling in primary TECs and TCMK-1 cells. (C) The TGF- $\beta$ 1 concentrations in supernatants of each 293T cell group. Immunoblot scoring of ATF3 and fibrotic markers in TCMK-1 cells. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .


A






B



C






**Figure S9. ATF3 overexpression aggravated fibrosis in TGF- $\beta$ 1 treated 293T cells.** (A) Quantitative real-time PCR analysis and immunoblot of ATF3 in 293T cells. (B) Quantitative real-time PCR analysis and immunoblots of fibrotic markers in 293T cells. (C) Quantitative real-time PCR analysis of *SMAD7* and immunoblots of TGF- $\beta$ /Smad3 signaling in 293T cells. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .





**Figure S10. The cell culture supernatants of TCMK-1 cells in each group stimulating NRK-49F cells could not affect fibrogenesis.** (A) Quantitative real-time PCR analysis, (B) immunoblots and (C) scorings of fibrotic markers in NRK-49F cells.



**Figure S11. The cell culture supernatants of 293T cells in each group stimulating NRK-49F cells could not affect fibrogenesis.** (A) Quantitative real-time PCR analysis, (B) immunoblots and (C) scorings of fibrotic markers in NRK-49F cells.